Corporate Banner
Satellite Banner
Technology Networks Header
Thursday, November 27, 2014
 
Register | Sign in
Home Page > Latest Webcasts
  Webcasts
Scientific News
New Advance in Cryopreservation Could Change Management of World Blood Supplies
Engineers have identified a method to rapidly prepare frozen red blood cells for transfusions.
New Study Reveals Why Some People May be Immune to HIV-1
Natural genetic variation in a protective antiviral enzyme holds promise for new therapies.
Protein Key To The Development Of Blood Stem Cells Identified
Understanding the self-replication mechanisms is critical for improving stem cell therapies for blood-related diseases and cancers.
Fast, Low-cost DNA Sequencing Technology One Step Closer To Reality
ASU Regents' Professor Stuart Lindsay led a team of scientists from Arizona State University's Biodesign Institute and IBM's T.J. Watson Research Center in the development of a prototype DNA reader that could make whole genome profiling an everyday practice in medicine.
Amazing Feet Of Science: Researchers Sequence The Centipede Genome
What it lacks in genes, it certainly makes up for in legs: the genome of the humble centipede has been found to have around 15,000 genes – around 7,000 fewer than a human.
New Genetic Markers To Combat Yellow Rust Disease In Wheat Identified
New study released identifying genetic markers that signal resistance to the wheat yellow rust pathogen.
Antibiotic Resistance Threatens Future of Modern Medicine
Overuse and misuse of antibiotics, one of the key contributors to antimicrobial resistance (AMR).
Pain In A Dish
Turning skin cells into pain-sensing neurons.
How the Environment Contributes to Human Diseases
Using a new imaging technique, NIH researchers have found that the biological machinery that builds DNA can insert molecules into the DNA strand that are damaged as a result of environmental exposures.
Monitoring Effectiveness Of Hay Fever Immunotherapy
A new test for measuring histamine release from certain white blood cells could help doctors monitor the effectiveness of immunotherapy for hay fever.
Scroll Up
Scroll Down
Return
The Versatility of Fragment Screening Approaches and the Application of Fragment Binding Information in Durg Discovery
Stefan Geschwindner, AstraZeneca, speaking at Discovery Chemistry Congress 2012.
Date Posted: Friday, November 23, 2012
Print Page

For access to this article, enter your email address to instantly recieve a Password Reset link.

Please enter your email address below:

Existing users please Sign In here. Don't have an account? Register Here for free access.

Don't have an account? | Register Here



AstraZeneca To Expand Its Frederick Biologics Manufacturing Center
$200+ million investment to support company’s maturing biologics pipeline.
Tuesday, November 25, 2014
AstraZeneca Buys Rights to Almirall Respiratory Franchise
AstraZeneca agrees an initial consideration of $875 million on completion, which may rise to $1.22 billion in development, launch, and sales-related milestones.
Monday, August 04, 2014
AstraZeneca Reveals Designs for Cambridge Headquarters
Company revealed the proposed designs for its new Global R&D Centre and Corporate Headquarters in Cambridge in the UK.
Friday, July 18, 2014
AstraZeneca system implemented with input from Tessella wins 2014 Bio-IT World Best Practices Award
Award winning Clinical & Health IT system allows AstraZeneca to respond rapidly to safety concerns and swiftly identify risk factors for adverse events, protecting trial participants while rescuing trials from costly late-stage failure.
Saturday, May 10, 2014
AstraZeneca Board Rejects Pfizer Proposal
The financial and other terms of the proposal have been described as inadequate, substantially undervaluing AstraZeneca.
Friday, May 02, 2014
AstraZeneca to Acquire Bristol-Myers Squibb Share of Global Diabetes Alliance Assets
Global agreement strengthens AstraZeneca’s commitment to diabetes.
Monday, December 23, 2013
AstraZeneca to Invest £120 Million in New Manufacturing Facility
AstraZeneca invests to continue production of Zoladex, an injectable treatment for patients with prostate cancer.
Tuesday, November 12, 2013
AstraZeneca to Acquire Pearl Therapeutics to Strengthen Respiratory Portfolio
Pearl Therapeutics is focused on the development of inhaled small-molecule therapeutics for respiratory disease.
Wednesday, June 12, 2013
AstraZeneca to Acquire Omthera Pharmaceuticals
Acquisition includes the take-over of NDA-ready novel dyslipidemia treatment to complement cardiovascular portfolio.
Wednesday, May 29, 2013
AstraZeneca and BMS Receive Award from Major Medical Association
Companies received the American College of Endocrinology (ACE) Philanthropic Award at the AACE 22nd Annual Scientific & Clinical Congress in Phoenix, Arizona on May 4, 2013.
Thursday, May 09, 2013
AstraZeneca’s Biologics Unit Acquires AlphaCore Pharma
AlphaCore Pharma is a biotechnology company focused on the development of ACP-501, a recombinant human lecithin-cholesterol acyltransferase enzyme.
Wednesday, April 03, 2013
AstraZeneca Announces Changes to Senior Executive Team
Company’s President and Executive Vice President will leave the company at the end of January.
Monday, January 28, 2013
Ten Pharmaceutical Companies Unite
Ten leading biopharmaceutical companies announced that they have formed a non-profit organization to accelerate the development of new medicines.
Wednesday, September 26, 2012
AstraZeneca and the Broad Institute Collaborate
Partnership to advance discovery of antibacterial and antiviral agents.
Tuesday, September 11, 2012
AstraZeneca Appoints Pascal Soriot CEO
Pascal Soriot will take on his new responsibilities and join the AstraZeneca PLC Board as an Executive Director on 1 October 2012.
Tuesday, August 28, 2012
 
Skyscraper Banner
Skyscraper Banner
Follow TechNetcom1 on Twitter
Technology Networks Ltd. on LinkedIn
Go to LabTube.tv